The optimal therapy for patients with EGFR-mutant NSCLC after osimertinib and platinum-based therapy is undefined, and patritumab deruxtecan has shown preliminary activity in this patient population.

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. Roche plans to invest nearly $300 million to build a new Chinese plant to ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

Timing and Outcomes of Palliative Care Integration Into Care of Adolescents and Young Adults With Advanced Cancer The advent of next-generation antibody-drug conjugates (ADCs), particularly ...

As a first-line treatment, the combination of datopotamab deruxtecan (Datroway; Dato-DXd) and durvalumab (Imfinzi) with or without carboplatin showed encouraging activity in patients with advanced or ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import ...

The US Food and Drug Administration (FDA) has approved Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade ...

Top-line results from the Phase III GLISTEN trial (NCT04950127) show that the novel therapy linerixibat produced a significant reduction in pruritus in adult patients with primary biliary cholangitis ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

The medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to treat more patients, specifically adults with HER2-low or HER2-ultralow ...